Infervision vs ScreenPoint Transpara
Breast screening programs and chest CT reading groups buy for different exams. ScreenPoint describes Transpara for 2D and 3D mammograms with single or double reading, and Infervision describes InferRead for CT and chest X-ray. Each tool has its own buyer.
A screening program weighing Transpara has the MASAI randomized trial in view. ScreenPoint says Transpara was the tool, and Lund University ran the trial. The vendor page claims 29% more cancers detected and 44% less workload, figures that come from a 2025 interim analysis and a 2023 one. The latest Transpara 510(k) is K260898 from August 2026.
A radiology group reading chest CT looks at Infervision. The InferRead Lung CT.AI page lists nodule detection with follow-up registration and volume doubling time, and the product was cleared in July 2020 and again in May 2025. InferRead CT Stroke.AI triages head CT and was cleared in August 2021.
Radiology · Reviewed November 2, 2026
Infervision
by Infervision · founded 2016
AI for CT lung nodules, CT stroke, surgical planning and RECIST follow-up, with FDA clearances for these CT products.
ScreenPoint Transpara
by ScreenPoint Medical
Transpara Breast AI: cancer detection support, density and risk tools for 2D and 3D mammograms.
When to pick each one
Infervision
- CT lung nodule detection cleared July 2020
- Head CT stroke triage cleared August 2021
ScreenPoint Transpara
- Detection support on 2D and 3D mammograms
- Latest Transpara 510(k) K260898, August 2026
- Vendor says it was the tool in MASAI
Score
Each row shows points earned of points available under the published rubric.
Infervision
57of 100
ScreenPoint Transpara
56of 100
| Dimension | Infervision | ScreenPoint Transpara | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 12.7 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 6 / 12 | +2.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Infervision
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
ScreenPoint Transpara
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Virtual demo and contact only. |
Evidence
Infervision
FDA decisions
K260973 (opens in new tab)510(k)2026-07-07
InferOperate Suite
K252261 (opens in new tab)510(k)2026-03-13
InferCare RECIST
K250237 (opens in new tab)510(k)2025-09-15
InferOperate Suite
K240554 (opens in new tab)510(k)2025-05-16
InferRead Lung CT.AI
K211179 (opens in new tab)510(k)2021-08-12
InferRead CT Stroke.AI
Show 1 more
K192880 (opens in new tab)510(k)2020-07-02
InferRead Lung CT.AI
Peer-reviewed
4 PubMed records name Infervision.
- Spatial classification of clinical T1a-bN0 non-small cell lung cancer in superior segment based on three-dimensional reconstruction: optimizing surgical margin and operative strategy. (opens in new tab)
- AI-assisted clinico-quantitative imaging nomogram for preoperative malignancy risk in solid and part-solid pulmonary nodules ≤ 3 cm: development and internal validation. (opens in new tab)
- Impact of dose reduction and iterative reconstruction algorithm on the detectability of pulmonary nodules by artificial intelligence. (opens in new tab)
ScreenPoint Transpara
FDA decisions
K260898 (opens in new tab)510(k)2026-08-14
Transpara (2.1.0)
K241831 (opens in new tab)510(k)2024-11-25
Transpara (2.1.0)
K232096 (opens in new tab)510(k)2023-12-11
Transpara Density 1.0.0
K221347 (opens in new tab)510(k)2022-08-03
Transpara 1.7.2
K210404 (opens in new tab)510(k)2021-06-02
Transpara 1.7.0
Show 3 more
K193229 (opens in new tab)510(k)2020-03-05
Transpara
K192287 (opens in new tab)510(k)2019-12-10
Transpara
K181704 (opens in new tab)510(k)2018-11-21
Transpara
Peer-reviewed
3 PubMed records name ScreenPoint Transpara.
- Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial. (opens in new tab)
- Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study. (opens in new tab)
- Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Infervision | ScreenPoint Transpara |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | n/a |
| HQ | n/a | NL |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.